Jamp To Offer Canadian Sitagliptin, Sandoz Bags Fixed-Dose Combo
Sandoz Launches Immediately, Jamp Says Product Available Soon
Executive Summary
An important mono- and adjunct therapy for diabetes patients now has generic competition in Canada, where an estimated 10% of the population are said to have been diagnosed with type 1 or type 2 diabetes.
You may also be interested in...
What’s Next? Five Things To Look Out For In April
Generics Bulletin previews the biggest events and changes for industry in the coming month.
Federal Court Shuts Down Viatris Sitagliptin Challenge Following West Virginia Defeat
Viatris has suffered a second defeat in its challenge to Merck’s sitagliptin dihydrogen phosphate exclusivity in the US Court of Appeals for the Federal Circuit, shortly after experiencing a similar blow in the District Court for the Northern District of West Virginia.
Viatris Loses US Challenge To Januvia And Janumet Patents
Viatris’ attempts to deliver US generic versions of sitagliptin and sitagliptin/metformin ahead of patent expiry has failed for now, with an unfavorable judgment from a district court in West Virginia. More than 20 ANDA sponsors have opted to settle litigation with originator Merck.